The IBN researchers who invented the more efficient DNA aptamer technology (from left: Mr Ken-ichiro Matsunaga, Dr Ichiro Hirao and Dr Michiko Kimoto).
A more efficient DNA technology to detect and treat infectious diseases and cancer has been developed by researchers at the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR.
The researchers improved on existing technologies to create a modified single-stranded DNA molecule called aptamer. DNA aptamers are ideal for pharmaceutical applications because they can specifically bind to any molecular target in the body such as proteins, viruses, bacteria and cells.
Once DNA aptamers are artificially generated for each target, they will bind to it and inhibit its activity. This makes DNA aptamers a promising technology for disease detection and drug delivery. But no DNA aptamers have been approved for clinical use yet because current aptamers do not bind well to molecular targets and are easily digested by enzymes.
“To overcome these challenges, we have created a DNA aptamer with strong binding ability and stability with superior efficacy. We hope to use our DNA aptamers as the platform technology for diagnostics and new drug development,” said IBN Executive Director Professor Jackie Y. Ying.
This study, led by IBN Principal Research Scientist and Team Leader Dr Ichiro Hirao, was recently published in the journal, Scientific Reports.
To tackle the weak binding problem, the research team added a new artificial component called unnatural base to a standard DNA aptamer, which typically has four components. The addition of the fifth component greatly enhanced the binding ability to the molecular target by 100 times as compared to conventional DNA aptamers. Furthermore, to prevent the aptamer from being digested easily by enzymes, a unique and small DNA called ‘mini-hairpin DNA’ was added to the DNA aptamer.
Dr Hirao explained, “The mini-hairpin DNAs have an unusually stable and compact stem-loop structure, like a hairpin, of small DNA fragments. Their structure strongly resists the digestive enzymes, so I added them to specific positions on the DNA aptamer to act as a protective shield. Usually DNAs are digested within one hour in blood at body temperature. With the mini-hairpin DNA, our DNA aptamers can survive for days instead of hours. This is important for pharmaceutical applications, which require the therapeutic to remain in the body for a longer period.”
If successfully commercialized, DNA aptamers could replace or complement the existing use of antibodies in drugs for targeted disease treatment. Like aptamers, antibodies bind to targets in the body, but often cause undesirable immune response and are not easy to mass produce with high quality.
“We can now generate very promising DNA aptamers for clinical use. Our aptamers are more efficient, and lower in cost and toxicity compared to conventional methods. The next step of our research is to use the aptamers to detect and deactivate target molecules and cells that cause infectious diseases, such as dengue, malaria and Methicillin-resistant Staphylococcus aureus, as well as cancer,” added Dr Hirao.
Read more: More Efficient DNA Technology for Targeted Disease Detection and Treatment
The Latest on: DNA technology
via Google News
The Latest on: DNA technology
- North American DNA Vaccine Market Size, Segmentation, Share, Forecast, Analysis, Industry Report to 2025on March 5, 2021 at 2:29 pm
The North American DNA Vaccine market is anticipated to grow at a CAGR 42.8% during the forecast period. North America is creating a significant opportunity for the DNA vaccination market. Several ...
- RNF8 ubiquitinates RecQL4 and promotes its dissociation from DNA double strand breakson March 5, 2021 at 12:36 pm
Ubiquitination-dependent DNA damage response (DDR) signals play a critical role in the cellular choice of DNA damage repair pathways. Human DNA helicase RecQL4 participates in DNA replication and ...
- Latin America DNA Vaccine Market will experience a noticeable growth during the forecast period 2019-2025: Orion Market Reportson March 5, 2021 at 4:12 am
Request a free sample of our report on Latin America DNA Vaccine Market: Further, the Latin-America market is analyzed on the basis of the countries that are contributing significantly towards the ...
- DNA evidence leads to arrest of Chicago man in Riverside ATM burglary caseon March 5, 2021 at 4:02 am
Blood left at a crime scene in Riverside has led to burglary charges against a Chicago man in connection to a ATM theft in the western suburb. DNA evidence showed that Demuiro D. Williams burglarized ...
- RevoluGen’s Automated Fire Monkey HMW-DNA Extraction Validated on Tecan Robot Supports Rapid Growth in Multiplexed DNA Sequencingon March 4, 2021 at 1:16 am
The UK genomic tools developer, RevoluGen Ltd. (RevoluGen or the Company), today announces the technology validation of the world’s first automated extraction of library-ready High Molecular Weight ...
- DNA Special: What is a 'Deepfake' and why this technology may be dangerous?on March 3, 2021 at 4:38 pm
What is a 'Deepfake' and why this technology may be dangerous? - Deepfake technology manipulates real photos or videos with the help of Artificial Intelligence, turning them into fake photos and ...
- Technology alliance boosts efforts to store data in DNAon March 3, 2021 at 7:17 am
These efforts got a lift last November, when a coalition of computing and biotech firms including Microsoft, Twist Bioscience, Illumina and Western Digital announced that they were forming the DNA ...
- Molecular Assemblies to Provide Enzymatic Synthesis Technology to DARPA NOW Project for On-Demand DNA/RNA Vaccine Manufacturingon March 2, 2021 at 12:33 pm
Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, today announced the company's participation in a new project with a multidisciplinary team, led by GE Research, to enable ...
- DNA Script Joins GE Research Collaboration to Develop On-Demand Vaccines and Therapeutics in Response to Biothreats for DARPA NOW Projecton March 2, 2021 at 11:05 am
DNA Script will receive up to $9.35 million to leverage the company's novel enzymatic DNA synthesis (EDS) technology for the project This is the ...
- Purigen Simplifies Simultaneous Extraction and Purification of DNA and RNA from Challenging FFPE Sampleson March 2, 2021 at 5:03 am
Purigen Biosystems, Inc., a leading provider of next-generation technologies for extracting and purifying nucleic acids from biological samples, today announced the launch of the Ionic® FFPE Complete ...
via Bing News